|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | When combination therapy isn't working: Emerging therapies for the management of inflammatory bowel disease显示文摘Although antagonists of tumor necrosis factor have resulted in major therapeutic benefits in inflammatory bowel disease, the magnitude and durability of response are variable. Similar to previously available drugs such as 5-aminosalicylates and immunomodulators, the therapeutic effect is not universal leaving many people searching for options. The development of newer agents has benefited from advances in the understanding of the pathophysiology of the disease. Uncontrolled activation of the acquired immune system has an important role, and lymphocytes, cytokines, and adhesion molecules are broadly targeted for therapeutic intervention. There is increasing evidence of an important role of the innate immune system and the intestinal epithelium, and the therapeutic paradigm is also shifting from immunosuppression to the reinforcement of the intestinal barrier, and modification of the disease process. In this review, we explore the limitation of current therapy as well as mechanisms of actions of new drugs and the efficacy and adverse events from data from clinical trials. | Suneeta Krishnareddy Arun Swaminath | 2014 | World Journal of Gastroenterology2014，20，5： | 4 |
| 2 | Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide显示文摘Methotrexate has been used an immunomodulator in many autoimmune diseases,including inflammatory bowel disease. However,many physicians are unfamiliar or uncomfortable with its use in the management of inflammatory bowel disease. We summarize the data for use of methotrexate in common clinical scenarios:(1) steroid dependant Crohn's disease(CD);(2) maintenance of remission in steroid free CD;(3) azathioprine failures in CD;(4) in combination therapy with Anti-TNF agents in CD;(5) decreasing antibody formation to Anti-TNF therapy in CD;(6) management of fistulizing disease in CD; and(7) as well as induction and maintenance of remission in ulcerative colitis. An easy to use algorithm is provided for the busy clinician to access and safely prescribe methotrexate for their inflammatory bowel disease patients. | Arun Swaminath Raja Taunk Garrett Lawlor | 2014 | World Journal of Gastrointestinal Pharmacology and Therapeutics2014，5，3： | 4 |
| 3 | Capsule endoscopy in Crohn's disease: Are we seeing any better?显示文摘Crohn's disease(CD) is a complex, immune-mediated disorder that often requires a multi-modality approach for optimal diagnosis and management. While traditional methods include ileocolonoscopy and radiologic modalities, increasingly, capsule endoscopy(CE) has been incorporated into the algorithm for both the diagnosis and monitoring of CD. Multiple studies have examined the utility of this emerging technology in the management of CD, and have compared it to other available modalities. CE offers a noninvasive approach to evaluate areas of the small bowel that are difficult to reach with traditional endoscopy. Furthermore, CE maybe favored in specific sub segments of patients with inflammatory bowel disease(IBD), such as those with IBD unclassified(IBD-U), pediatric patients and patients with CD who have previously undergone surgery. | David Hudesman Jonathan Mazurek Arun Swaminath | 2014 | World Journal of Gastroenterology2014，20，36： | 2 |
| 4 | Microbial manipulation as primary therapy for Crohn's disease显示文摘While antimicrobials are clinically effective in preventing post-operative recurrence,the role for antibiotics in primary therapy for Crohn's disease(CD) remains unclear.The recent multicenter phase 2 trial by Prantera et al received wide attention because it demonstrated an increase in the week 12 remission rate in patients with moderately active CD treated with rifaximin and renewed interest in microbial manipulation as primary therapy for CD.In this commentary,we discuss aspects of durability,immune cell polarization,and safety of microbial manipulation as primary therapy for CD. | Randy S Longman Arun Swaminath | 2013 | World Journal of Gastroenterology2013，19，10： | 2 |
| 5 | Review of inflammatory bowel disease and COVID-19显示文摘The first cases of a novel corona virus infection were reported in Wuhan China in December of 2019,followed by the declaration of an international pandemic by the World Health Organization in March 2020.Early reports of the virus,now known as severe acute respiratory syndrome coronavirus 2,and its clinical disease coronavirus disease 2019(COVID-19),has shown higher rates of morbidity and mortality in the elderly and those with pre-existing medical conditions.Of particular concern is the safety of those with compromised immune systems.Inflammatory Bowel disease(IBD)is itself caused by a disordered immune response,with the most effective medical therapies being immune suppressing or modifying.As such,the risk of COVID-19,virus related outcomes,and appropriate management of IBD patients during the global pandemic is of immediate concern to gastroenterologists worldwide.There has been a rapid accumulation of clinical data and expert opinion on the topic.This review will highlight the latest source information on clinical observation/outcomes of the IBD population and provide a concise summary of the most up to date perspectives on IBD management in the age of COVID-19. | Keith Sultan Anjali Mone Laura Durbin Samreen Khuwaja Arun Swaminath | 2020 | World Journal of Gastroenterology2020，26，37： | 1 |
| 6 | Endo-hepatology:An emerging field显示文摘Gastroenterologists have long been spearheading the care of patients with various forms of liver disease.The diagnosis and management of liver disease has traditionally been a combination of clinical,laboratory,and imaging findings coupled with percutaneous and intravascular procedures with endoscopy largely limited to screening for and therapy of esophageal and gastric varices.As the applications of diagnostic and therapeutic endoscopic ultrasound(EUS)have evolved,it has found a particular niche within hepatology now coined.Here we discuss several EUS-guided procedures such as liver biopsy,shear wave elastography,direct portal pressure measurement,paracentesis,as well as EUSguided therapies for variceal hemorrhage. | Daniel E Hogan Michael Ma David Kadosh Alisha Menon Kana Chin Arun Swaminath | 2021 | World Journal of Gastrointestinal Endoscopy2021，13，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员